What should clinics know about compounded peptides?

Clinics exploring compounded peptides need a clear-eyed view of how a compounded preparation differs from an approved peptide drug, and what to check before offering either to patients.

Approved vs. compounded: the core difference. An approved peptide drug reaches the market through a formal review pathway, with fixed labeling, validated manufacturing, and post-market surveillance. A compounded preparation is made by a pharmacy to fill a prescription for an individual patient; it is not a generic equivalent and is not interchangeable with the approved product. Clinics should treat compounded peptides as a separate product category with its own risk profile, not as a cheaper copy of an approved drug.

Quality considerations. Ask the compounding partner for documentation on the peptide source (API origin and certificate of analysis), identity and purity testing, sterility and endotoxin testing for injectables, and stability data supporting the beyond-use date. Confirm the pharmacy's licensing and inspection history, and whether it handles sterile compounding. For lyophilized vials, verify reconstitution instructions and storage requirements. Clinics should also confirm lot traceability so a patient issue can be traced back to a batch.

Clinical considerations. Compounded peptides may lack the large clinical trials behind approved products, so dosing, titration, and monitoring should be conservative and documented. Clinics should set internal protocols for patient selection, baseline labs, follow-up intervals, and adverse-event reporting. Informed consent should explain that the preparation is compounded, what is and is not known about its evidence base, and how it differs from an approved alternative. Staff should be trained to recognize and report reactions.

Operational and supply considerations. Clinics should vet their supply chain end to end: the pharmacy, the API source, and the logistics provider. Cold-chain integrity, shipping time, and packaging matter for peptide stability. Clinics comparing pharmacies, manufacturers, or logistics partners can use our service items 22–25 (helping peptide therapy clinics compare 503A pharmacies, 503B manufacturers, dual-chamber cartridge and pen suppliers, and China-based peptide international logistics providers). Clinics that also source research-grade materials for lab use can reference items 8–12, and those needing trade, legal, customs, or door-to-door logistics support can reference items 33–36.

Practical checklist for clinics.

• Confirm the legal status of the specific compounded peptide and the pharmacy's authority to make it.
• Collect certificates of analysis, sterility/endotoxin results, and stability data for each lot.
• Document informed consent that distinguishes compounded from approved products.
• Set dosing, monitoring, and adverse-event protocols before the first patient.
• Audit the full chain: API source, compounding pharmacy, and shipping/logistics.
• Keep records that allow lot-level traceability and recall response.

In short, clinics should know that compounded peptides are a distinct category requiring their own quality checks, clinical guardrails, and supply-chain diligence, and should not be presented to patients as equivalent to an approved peptide drug.